Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsTitle - concise and clear - No Remarks
Abstract - clearly defining the essence of the study -
row 46 - IO cohort? - abbreviation needs clarification - MINOR
introduction - elegant presentation on the current knowledge on the subject, and the different approaches for ICI inclusion in therapy of a/m urothelial cancer
row 70 PDL-1 ? typo? Minor
row 87 - IO ? - needs clarification
Material and Methods - No Remarks
Results
row 141 - "Median OS was similar in the D, V and cohorts (15.3 months vs 14.2 months vs 14.6 months, p=0.889)" - third cohort is missing, what is this third cohort? - MAJOR table 1 - primary tumor location - Upper Tract (Bladder) ???
Lower tract (ureter, renal pelvis)???? - MAJOR - serious discrepancy Type of chemo treatment (n, %) - row misalignment - MAJOR
Pretreatment performance status (ECOG) (n,%) - extremely high rate of unknown in chemo group (52 %) - potential significant source of bias in OS assessment - needs comment - Major
Circulating inflammatory markers (median, range) - row misalignment - MAJOR Radiological response (n, %) - extremely high rate of non-evaluable in chemo group (55%) - potential significant source of bias in PFS assessment - needs comment - Major Discussion - No remarks - nicely implementing the authors results into the contemporary literature and strongly substantiating their conclusions
Author Response
please see the attachment
Author Response File: Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsThe manuscript "Development and validation of the U-IPI index to predict out- comes in advanced/metastatic urothelial cancer patients receiving immune checkpoint inhibitors" aims to develop and validate an immune prognostic index for advanced/metastatic urothelial cancer. The manuscript brings novelty to urothelial cancer prognosis and treatment, due to the identification of an inflammatory profile able to stratify the patients.
In the abstract, provide the acronym for LDH.
The discussion should be improved. The authors could discuss more the results otained and the inflammatory parameters with the literature.
Author Response
Please see the attachment.
Author Response File: Author Response.pdf
Round 2
Reviewer 1 Report
Comments and Suggestions for Authorsthe authors has taken into account this reviewer`s recommendations